Agios Pharmaceuticals said Monday that its pill Pyrukynd increased levels of hemoglobin in more sickle cell disease patients than placebo, and it plans to start a Phase III trial later this year.
Pyrukynd is already approved for a rare genetic disease known as pyruvate kinase deficiency, and Agios is looking to expand its label into more prevalent blood diseases, such as sickle cell disease and thalassemia.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters